The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
X4 Pharmaceuticals is on track to complete enrollment of its Phase 3 4WARD trial for mavorixafor in chronic neutropenia by Q3 2026, targeting a 2028 launch. The European Commission approved XOLREMDI for WHIM syndrome, while the company cuts costs and deprioritizes WHIM commercialization.
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
Korean biotech firms will present next-generation cancer therapies at the AACR meeting, including CAR-T platforms for solid tumors, mRNA-based treatments, radiopharmaceuticals, and bispecific antibody ADCs. Companies like AbClon, Verismo Therapeutics, Hanmi Pharmaceutical, and SK Biopharmaceuticals will showcase their latest research.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
Two Nature Chemical Biology studies described new routes to molecular glue discovery. One identified ZZ1 and YPEL5-linked CTLH recruitment, while another found an ENL degrader in leukemia cells.
Blackstone closed its sixth dedicated life sciences fund at a $6.3 billion hard cap, the largest private fund raised for the sector. The vehicle is nearly 40% larger than its 2020 predecessor and targets late-stage drug assets.
The cell therapy manufacturing market is projected to reach $14.01 billion by 2035, with CAR-T therapies dominating at 65% market share. Recent FDA approvals for new CAR-T indications and Japanese regulatory acceleration highlight growing clinical adoption, while research advances include new anti-aging protein platforms and CRISPR-based treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07556757 |
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia |
RECRUITING | PHASE1 |
| NCT07524530 |
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers |
NOT_YET_RECRUITING | PHASE2 |
| NCT07512882 |
Cohort of Patients With Chronic Myelomonocytic Leukemia |
RECRUITING | |
| NCT07483749 |
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors |
NOT_YET_RECRUITING | |
| NCT07439211 |
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia |
NOT_YET_RECRUITING | PHASE1 |
| NCT07405424 |
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia |
RECRUITING | NA |
| NCT07374315 |
Weight Gain in Pediatric Leukemia Survivors |
NOT_YET_RECRUITING | NA |
| NCT07356154 |
A Study of Revumenib and Mezigdomide in People With Leukemia |
RECRUITING | PHASE1/PHASE2 |
| NCT07347171 |
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies |
RECRUITING | PHASE1 |
